ArticleScientific reports2025
Innovative design and comprehensive characterization of a valine-enhanced lipid nanoparticle-coated mRNA vaccine targeting the SARS-CoV-2 S-RBD antigen.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- AI-aided engineering and production optimization of chimeric hetero-viral capping enzymes for mRNA vaccines.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The SARS-CoV-2 pandemic has led to major advances in mRNA vaccine development. This study aimed to develop a cationic lipid nanoparticle (LNP) coated mRNA vaccine targeting the receptor binding domain (RBD) against the SARS-CoV-2 virus and adding valine to the N-terminal end to increase its stability, and to comprehensively characterize the physical, thermal, microscopic and biological properties of vaccine. The vaccine was designed in silico and valine-added S-RBD molecule was generated by IVT. The LNP coated mRNA vaccine was evaluated by spectroscopic (UV-vis, FT-IR, Raman), thermodynamic (TGA/DSC), microscopic (STEM, AFM), size/potential (DLS) and surface tension analysis methods. The developed vaccine was analyzed for cytotoxicity (MTT) and pro/anti-inflammatory gene expression (qPCR). Spectroscopic analyses revealed distinct RNA and lipid peaks. Thermodynamic analyses revealed complete mass loss for mRNA and LNP at 136.2 °C and 85.7 °C, respectively. STEM analysis revealed that mRNA was uniformly coated with LNP, and its size was < 100 nm, and Ra/Rz values were 26.56/34.29 nm, respectively. Zeta potentials ranged from 0 to - 30 mV, and surface tensions were 33.8-38.0 mN/m, respectively. MTT analysis showed that the vaccine was not cytotoxic. qPCR analysis, significant increases were detected in IFNA1, IFNB1 and TNF gene expressions, but no significant increase was detected in IL6. Bioinformatic analyses revealed increased stability in mRNA structure and more robust pseudoknot formations after valine addition. Our study is the first study in which a uniquely designed valine-added mRNA vaccine coated with LNP targeting the RBD antigen of SARS-CoV-2 was developed and comprehensively characterized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.